Pfizer is investing $120 million in a Michigan factory to dramatically increase its production and supply of its oral COVID-19 treatment, the pharmaceutical company announced Monday.
The investment, which will create more than 250 high-skilled jobs at the Kalamazoo plant, will be used to increase production of the active ingredient in Paxlovid.
“Pfizer Global Supply has made the impossible possible, manufacturing billions of doses of vaccines and now millions of courses of treatment to help fight the deadly COVID-19 pandemic,” Pfizer CEO Albert Bourla said in a statement. release.
“By ramping up production at our Michigan facility, we are helping patients around the world and bringing important manufacturing innovations to the U.S. leadership.”
The Kalamazoo factory will be able to produce 1,200 metric tons of the active pharmaceutical ingredient in Paxlovid annually, Pfizer said. A spokesman told the Daily News that this capability will increase the supply of the drug by 4 million packs.
“Pfizer’s $120 million expansion in Kalamazoo, which will create 250 high-paying jobs to support Paxlovid manufacturing, will build on Michigan’s economic momentum,” the Michigan governor said. Gretchen Whitmer said in a statement.
The oral treatment, approved for emergency use for ages 12 and older with mild-to-moderate COVID-19, has been shown to reduce hospitalization and death by nearly 90% if taken within five days of symptom onset , according to Pfizer.